Chemomab Therapeutics Ltd. — Form SCHEDULE 13D/A
Filed September 9, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
HBM Healthcare Investments (Cayman) Ltd. filed an amended Schedule 13D/A regarding beneficial ownership in Chemomab Therapeutics Ltd. (public market value ~$37.9M). The filing document itself contains no substantive disclosures of specific share counts, percentages, dollar amounts, or changes to ownership position—only administrative headers and metadata indicating an amendment was submitted on 2026-09-09.
Why this rating
Amendment to 13D is routine disclosure; no material ownership change, transaction amount, or business impact specified in filing text.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.